This publication by Joel G. Breman discusses the multifaceted challenges posed by malaria, including its symptoms, burden on health systems, and impacts on mothers and children. It outlines the transmission dynamics of Plasmodium species, the associated health complications like anemia and cerebral malaria, and the vital interventions needed to combat malaria. Additionally, it presents goals for malaria control, highlights ongoing research, and advocates for strategies aimed at achieving significant reductions in malaria incidence and mortality, particularly in vulnerable populations.
01 / 52Defining and Defeating the Intolerable Burden of Malaria
1 / 17
Télécharger la présentation
Defining and Defeating the Intolerable Burden of Malaria
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation
Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement.Téléchargez la présentation en cliquant sur ce lien.Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.
F I N
Plus de contenu associé
Transcription de la présentation
Defining and Defeating the Intolerable Burden of Malaria Joel G. Breman, MD, DTPH Fogarty International Center U.S. National Institutes of Health BioVisionAlexandria 2008 New Life Sciences: From Promises to Practice Alexandria, Egypt April 14, 2008
Manifestations of the Malaria Burden Anemia Long-term sequelae Hypoglycemia Acute febrile illness Severe illness Respiratory distress Death Hypovolemia Infected Mosquito Cerebral malaria Anemia Chronic effects Impaired growth and development Neurologic Cognitive Infected Human Malnutrition Developmental Low birth weight Abortion, stillbirth Infant and fetal mortality Fetus Pregnancy Acute illness Long-term sequelae Maternal Anemia Breman, Alilio, Mills, 2004, Am J Trop Med Hyg
Overlap of Cerebral Malaria, Anemia, Respiratory Distress in Children Mali Kenya 31/58 (53%) Marsh et al, 1995, NEJM Ranque et al 2008, Ped Inf Dis J ( ) = number of patients % = CFR
Burden of Malaria on Health Systems in Sub-Saharan Africa, 1999-2004 Total DALYs% HIV/AIDS 17.8 Malaria10.3 Lower respiratory infections 8.4 Perinatal conditions 6.3 Diarrheal diseases 6.1 Measles 4.6 Tuberculosis 2.4 Whooping cough 1.9 Road traffic accidents 1.8 Protein-energy malnutrition 1.6 Total61.2 Leading Causes of Disability-Adjusted Life Years (DALYs) in Sub-Saharan African Region, 2001 FEVER HISTORY OUTPATIENTS DEATHS ADMISSIONS HOSPITAL Source: Mathers, et al., 2006, Global Burden of Disease and Risk Factors Source: WHO 2005
Deaths from Malaria: Children Under Fiveand Total, Africa 2001 Number of malaria deaths Cause of malaria-related death • Under fives Severe anemia 190,000-974,000 Hypoglycemia 153,000-267,000 Low birth weight 62,000-363,000 Cerebral malaria 110,000 Respiratory distress 110,000 Total deaths from malaria 625,000-1,824,000 962,000-2,806,000 • Total, all ages Sources Breman, Alilio and Mills, 2004, Am J Trop Med Hyg; Murphy and Breman, 2001, Am J Trop Med Hyg
Malaria Cases and Death in South East Asia Region of WHO, 2004 DEMOCRATIC PEOPLE’S REPUBLIC OF KOREA 0.5% Malaria Cases = 2,525,715 Malaria Deaths = 3,768 Malaria Danger in Central Asia and Kazakhstan Cases of Malaria in the European Region , 2005 Breman and Holloway, 2007 Am J Trop Med Hyg
RBM strategy Prompt access to effective treatment Insecticide-treated nets (ITNs) Prevention and control in pregnant women Epidemics Abuja target (by 2005), RBM (2007) 80% patients using correct/affordable treatment w/in 24 hrs 80% of children <5 years and pregnant women having ITNs 80% of pregnant women using intermittent preventive treatment 60% detected w/in 2 weeks of onset 60% responded to w/in 2 weeks Roll Back Malaria’s Goals, Strategies, and Targets To Halve the Burden of Malaria by 2010Abuja Malaria Summit, April 2000, revised 2007 RBM, WHO, 2008
Major Manifestations of Malaria Anemia Lennart Nielson (Karolinska Instituteg), Hedvig Perlmann (Stockholm University) Martin Weber Cerebral malaria Roll Back Malaria Info Sheet George Grau Low birthweight Rick Steketee National Human Genome Research Institute
Selected Severe Clinical Malaria Conditions Requiring Diagnosis, Assessment and Reporting (2) * * * a in addition to antimalarial drugs; referral to a secondary or temporary care facility for patients requiring parenteral therapy and intensive supportive care. b consider exchange transfusion for parasitemia >10% * essential measurement Breman and Holloway, 2007, Am J Trop Med Hyg
Control of the Malaria Burden Current Interventions Drugs (treatment, prevention) Protection (insecticide-impregnated materials) Insecticides (house spraying, larvicides) Environmental and Behavioral Modification Vaccines (preerythrocytic, blood stage, transmission-blocking) Genetic modification of vectors Future Interventions
Cost-Effectiveness of Interventions Against Malaria in Sub-Saharan Africa Intermittent preventive treatment/ pregnancy (SP) Insecticide residual spraying Artemisinin comb. therapy (resistance) Insecticide-treated bed nets Intermittent preventive treatment 0 5 10 15 20 25 30 Cost-effectiveness ratio ($ per DALY averted) Laxminarayan et al (DCPP authors), 2006, in Jamison et al, Disease Control Priorities in Developing Countries, 2nd ed.
Malaria: Prevention and Treatment • Treatment with a new group of antimalarials – the artemisinin compounds, in combination with lumefantrine, amodiaquine, sulfadoxine–pyrimethamine, or others Artemesia annua Spread of chloroquine resistance
9000 8000 7000 DDT 6000 OP 5000 4000 C thousands of kg 3000 PY 2000 1000 0 1995 1997 1998 2001 2004 1996 1999 2000 2002 2003 2005 thousands of kg Insecticides Used for Malaria Vector Control, 1995-2006 Vector Surveillance Capacity in Sub-Saharan Africa, 2006 Entomological Capacity, 2006 no capacity basic for control or research basic/advanced for control, advanced in research WHO, 2004, Sadasavaiah, Tozan, Breman, 2007
Rwanda: Malaria Progress Vital Statistics Population: 9.3 million Women 15-45 yrs: 2.7 million Children <5 yrs: 4.0 million Infant mortality: 152 (2005) Malaria Risk: 4.8 million Cases: 1.4 million (2005) Deaths <5yrs: 510 (2006) Roll Back Malaria
Ethiopia: Malaria Progress Vital Statistics Population: 77.3 million < 5 mortality: 123 Malaria Risk: 52.5 million Cases (est): 12 million (2006) (reported): 3.7 million Child Deaths : 94,400 Roll Back Malaria
Zambia: Malaria Progress Malaria Cases: 2.1 million (2005) Vital Statistics Population: 11.7 million Roll Back Malaria
Results from Zanzibar Outpatient Malaria Cases (Confirmed and non-confirmed) per 1000 of the population Proportion of malaria confirmed cases Ali, et al 2007, EARN Meeting
Research Needs: Disease Burden that Can or Cannot be Averted with Existing Interventions Disease Burden: Biomedical research to identify new and improved interventions Not Avertable Increase effectiveness or reduce costs of existing interventions Already averted Avertable coverage Broader implementation of cost-effective interventions; identify obstacles to expansion of coverage
Research and Development Categories and Results for Implementation New basic understanding • Fundamental research • Basic epidemiology, risk factors, modeling New and improved tools • Drugs • Vaccines • Diagnostics • Devices • Vector control • Environmental modification • Behavioral, social, and economic change
Research and Development Categories and Results for Implementation New and improved intervention methods • Treatment algorithms and guidelines • Intervention packaging • Priority setting via costing and cost-effectiveness studies • Delivery: health systems and health services • New and improved policy instruments
Multiple pathologies Anemia Low birthweight Malnutrition HIV Enteritis Sepsis Neurocognitive Neglected diseases Host factors Immunity and vaccines Genetic susceptibility Plasmodium falciparum vivax Antigenic diversity Drug resistance Anopheles Transmission dynamics Human Correlation of Entomologic Inoculation Rate with clinical manifestations Special conditions Epidemics Urbanization Migration Malaria Research Needs: Major Gaps and Controversies Requiring Attention